Dr Rawstron qualified from Edinburgh University with a BSc
in Immunology in 1992. He became a Clinical Scientist at the Haematological
Malignancy Diagnostic Service in Leeds and was awarded a Doctorate of
Philosophy in 2002.
Dr Rawstron's work into the understanding of CLL, both in
terms of defining the nature of Monoclonal B-Lymphocytosis and in developing
and standardizing the assessment of minimal residual disease (MRD) in CLL, has
been internationally recognized. His work in coordinating a standard approach
to MRD analysis in CLL has encouraged close collaboration between many of the
laboratories on the cutting edge of CLL research.
You can see my upcoming and previous webinars here.
